Compare AUPH & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUPH | IMAX |
|---|---|---|
| Founded | 1993 | 1967 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2014 | 1997 |
| Metric | AUPH | IMAX |
|---|---|---|
| Price | $14.25 | $37.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $17.25 | ★ $44.44 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | 31.25 |
| EPS | ★ 2.07 | 0.63 |
| Revenue | $283,055,000.00 | ★ $410,212,000.00 |
| Revenue This Year | $16.53 | $9.80 |
| Revenue Next Year | $16.24 | $7.11 |
| P/E Ratio | ★ $7.06 | $59.92 |
| Revenue Growth | ★ 20.38 | 16.47 |
| 52 Week Low | $6.83 | $20.48 |
| 52 Week High | $16.54 | $43.16 |
| Indicator | AUPH | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 44.75 |
| Support Level | $13.52 | $35.91 |
| Resistance Level | $15.23 | $37.52 |
| Average True Range (ATR) | 0.45 | 1.12 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 36.73 | 32.17 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.